Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Stem Cells Transplanted in Monkeys Without Anti-Rejection Drugs

By Drug Discovery Trends Editor | September 19, 2016

Scientists report they have successfully transplanted reprogrammed monkey stem cells into the eyes of other monkeys without the need for anti-rejection drugs.

The techniques used in this study have been in development for some time.

The long-term goal is to replace damaged tissues or organs one day with healthy new ones grown in a lab using stem cells.

Adult human cells can already be reprogrammed into stem cells and then grown into specific cell types. To avoid rejection, these cells have to be grown from someone’s own skin cells.

A research team at the RIKEN Center for Developmental Biology in Japan started a transplant trial involving patients with age-related macular degeneration and stem cells grown from their own skin cells.

The scientists grew retinal pigment cells from adult cells called induced pluripotent stem cells (iPSCs). The new cells were transplanted into patients with a damaged retina. Since the iPSCs were created from the patients’ own skin cells, rejection wasn’t an issue.

Although promising, this technique is expensive. It’s also time-consuming. The cells used must grow at the typical rate of development. As a result, patients would have to wait more than one year before they could receive their transplant.

“In order to make iPSC transplantation a practical reality, the current goal is to create banks of iPSC-derived tissues that can be transplanted into anyone as they are needed,” study author Dr. Sunao Sugita said in a RIKEN news release.

“However, immune responses and tissue rejection are big issues to overcome when transplanting tissue derived from other individuals,” Sugita said.

For the new study, the researchers tested another method to avoid rejection known as major histocompatibility complex (MHC) matching. MHCs are found in every cell. In people, MHCs are also known as human leukocyte antigens (HLAs). They are sets of proteins from cell surfaces that function in the immune system.

There are many genetic variations of MHCs. If someone undergoes a transplant and their donor MHCs are not recognized by their own T-cells, their immune system will trigger a response and reject the new tissue, the study authors said.

To assess the effectiveness of MHC matching, the researchers behind the new study took retinal pigment cells from a stem cell bank that were grown from monkey iPSCs and transplanted them into the eyes of other monkeys. Some monkeys were given genetically matched MHCs, while others received mismatched MHCs.

Rejection occurred fairly quickly among the MHC-mismatched monkeys, the study showed.

But the transplanted cells in the MHC-matched monkeys survived without rejection for at least six months with no use of drugs to weaken the immune system. Helper immune system cells known as T-cells did not respond to the transplanted retinal pigment cells if they were from an MHC-matched monkey, the study found.

These results were published Sept. 15 in Stem Cell Reports.

In a second study in the same issue of the journal, the researchers repeated these experiments using human cells in the lab. The results were similar to the monkey trial.

Sugita added that the findings from their next clinical trial will let them know if the cell bank will be truly useful in humans or not.

It’s important to note that research involving animals often fails to produce similar results in humans.


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE